At the news
? NEUTRALIMPACT 6/10 6-K filed Aug 31, 2026 at 16:06 ET
Ascendis Pharma announced a binding term sheet for a global settlement and license agreement with BioMarin, resolving all litigation over YUVIWEL and navepegritide-related products. Ascendis will pay royalties of 20% in the US and 18% in the EU/South Korea/Brazil from first commercial sale of YUVIWEL through May 2030. The settlement provides critical IP certainty for Ascendis's pipeline but imposes a significant royalty burden on future sales.
- Binding term sheet signed for global settlement and license agreement with BioMarin on August 31, 2026.
- BioMarin grants non-exclusive, worldwide, royalty-bearing license for navepegritide-related products.
- Ascendis to make royalty payments: 20% of net sales in the United States, 18% in the EU, South Korea, and Brazil.
- Royalties run from first commercial sale of YUVIWEL in each country through May 20, 2030.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access